These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21787763)

  • 1. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
    Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
    Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
    Favoni RE; Pattarozzi A; Lo Casto M; Barbieri F; Gatti M; Paleari L; Bajetto A; Porcile C; Gaudino G; Mutti L; Corte G; Florio T
    Curr Cancer Drug Targets; 2010 Mar; 10(2):176-91. PubMed ID: 20088784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA; Taffaro ML; Salgia R; Johnson BE
    Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
    Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
    Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
    Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors.
    Liu Z; Klominek J
    Neoplasia; 2004; 6(6):705-12. PubMed ID: 15720796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
    Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
    Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM; Saigal B; Donato NJ
    J Cell Physiol; 2005 Nov; 205(2):218-27. PubMed ID: 15887238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells.
    Pédeboscq S; Gravier D; Casadebaig F; Hou G; Gissot A; De Giorgi F; Ichas F; Cambar J; Pometan JP
    Eur J Med Chem; 2010 Jun; 45(6):2473-9. PubMed ID: 20219270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
    Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
    Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
    Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
    Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of taspine by modulating the EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo.
    Zhang Y; Zheng L; Zhang J; Dai B; Wang N; Chen Y; He L
    Planta Med; 2011 Nov; 77(16):1774-81. PubMed ID: 21614750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?
    Agarwal V; Lind MJ; Cawkwell L
    Cancer Treat Rev; 2011 Nov; 37(7):533-42. PubMed ID: 21183281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
    Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
    Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
    Garland LL; Rankin C; Gandara DR; Rivkin SE; Scott KM; Nagle RB; Klein-Szanto AJ; Testa JR; Altomare DA; Borden EC
    J Clin Oncol; 2007 Jun; 25(17):2406-13. PubMed ID: 17557954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
    Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
    Kinsella P; Howley R; Doolan P; Clarke C; Madden SF; Clynes M; Farrell M; Amberger-Murphy V
    Exp Cell Res; 2012 Mar; 318(5):641-52. PubMed ID: 22285130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.